Massachusetts Financial Services Co. MA Grows Holdings in Amicus Therapeutics, Inc. (FOLD)

Massachusetts Financial Services Co. MA raised its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 25.8% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 976,570 shares of the biopharmaceutical company’s stock after purchasing an additional 200,340 shares during the period. Massachusetts Financial Services Co. MA owned 0.52% of Amicus Therapeutics worth $11,807,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in the business. BlackRock Inc. lifted its position in Amicus Therapeutics by 6.1% during the 2nd quarter. BlackRock Inc. now owns 16,017,301 shares of the biopharmaceutical company’s stock valued at $250,190,000 after purchasing an additional 927,049 shares during the period. Morgan Stanley lifted its position in Amicus Therapeutics by 519.6% during the 2nd quarter. Morgan Stanley now owns 4,968,627 shares of the biopharmaceutical company’s stock valued at $77,610,000 after purchasing an additional 4,166,756 shares during the period. Victory Capital Management Inc. lifted its position in Amicus Therapeutics by 18.0% during the 2nd quarter. Victory Capital Management Inc. now owns 3,606,039 shares of the biopharmaceutical company’s stock valued at $56,325,000 after purchasing an additional 550,740 shares during the period. Northern Trust Corp lifted its position in Amicus Therapeutics by 9.3% during the 2nd quarter. Northern Trust Corp now owns 2,394,490 shares of the biopharmaceutical company’s stock valued at $37,401,000 after purchasing an additional 203,444 shares during the period. Finally, Bank of New York Mellon Corp lifted its position in Amicus Therapeutics by 0.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 2,046,768 shares of the biopharmaceutical company’s stock valued at $31,970,000 after purchasing an additional 6,931 shares during the period.

In other Amicus Therapeutics news, major shareholder Life Sciences Maste Perceptive bought 50,000 shares of the stock in a transaction that occurred on Friday, September 21st. The stock was acquired at an average cost of $12.53 per share, with a total value of $626,500.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, major shareholder Perceptive Advisors Llc bought 20,000 shares of the stock in a transaction that occurred on Monday, September 24th. The shares were acquired at an average cost of $12.45 per share, with a total value of $249,000.00. The disclosure for this purchase can be found here. Insiders purchased a total of 620,000 shares of company stock worth $7,505,000 over the last quarter. 2.90% of the stock is currently owned by corporate insiders.

Shares of NASDAQ:FOLD opened at $11.14 on Wednesday. The company has a debt-to-equity ratio of 0.30, a current ratio of 10.88 and a quick ratio of 10.73. Amicus Therapeutics, Inc. has a fifty-two week low of $10.33 and a fifty-two week high of $17.62.

Amicus Therapeutics (NASDAQ:FOLD) last announced its quarterly earnings results on Monday, November 5th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.04). The firm had revenue of $20.60 million during the quarter, compared to analyst estimates of $23.56 million. Amicus Therapeutics had a negative net margin of 460.04% and a negative return on equity of 53.45%. The business’s revenue was up 89.0% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.41) earnings per share. On average, equities analysts anticipate that Amicus Therapeutics, Inc. will post -1.19 earnings per share for the current year.

A number of brokerages recently weighed in on FOLD. BidaskClub upgraded shares of Amicus Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Tuesday. Chardan Capital downgraded shares of Amicus Therapeutics from a “buy” rating to a “neutral” rating and cut their price target for the company from $18.00 to $15.00 in a research report on Friday, August 17th. Cowen reiterated a “buy” rating and issued a $31.00 price target on shares of Amicus Therapeutics in a research report on Friday, October 12th. Zacks Investment Research upgraded shares of Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $18.00 price target on the stock in a research report on Tuesday, July 10th. Finally, Citigroup began coverage on shares of Amicus Therapeutics in a research report on Monday, October 29th. They issued a “neutral” rating and a $12.00 price target on the stock. One research analyst has rated the stock with a sell rating, two have issued a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $19.50.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by WKRB News and is owned by of WKRB News. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.wkrb13.com/2018/11/07/massachusetts-financial-services-co-ma-grows-holdings-in-amicus-therapeutics-inc-fold.html.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 to investigate in patients with pompe disease.

Read More: 52-Week High/Low

Institutional Ownership by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply